Cargando…

Safety of Re-dosing Nirsevimab Prior to RSV Season 2 in Children With Heart or Lung Disease

In children with congenital heart disease and/or chronic lung disease entering their second respiratory syncytial virus (RSV) season, 200 mg nirsevimab had a similar safety profile to that of palivizumab and resulted in nirsevimab serum exposures associated with efficacy in healthy infants, supporti...

Descripción completa

Detalles Bibliográficos
Autores principales:	Domachowske, Joseph B, Chang, Yue, Atanasova, Victoria, Cabañas, Fernando, Furuno, Kenji, Nguyen, Kim A, Banu, Irfana, Kubiak, Robert J, Leach, Amanda, Mankad, Vaishali S, Shroff, Manish, Takas, Therese, Villafana, Tonya, Wählby Hamrén, Ulrika
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Brief Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10469583/ https://www.ncbi.nlm.nih.gov/pubmed/37466917 http://dx.doi.org/10.1093/jpids/piad052

Ejemplares similares

LB13. The Efficacy and Impact in Heathy Infants of Nirsevimab on Medically Attended RSV Lower Respiratory Tract Infection
por: Hammitt, Laura, et al.
Publicado: (2021)

Durability of neutralizing RSV antibodies following nirsevimab administration and elicitation of the natural immune response to RSV infection in infants
por: Wilkins, Deidre, et al.
Publicado: (2023)

Molecular and phenotypic characteristics of RSV infections in infants during two nirsevimab randomized clinical trials
por: Ahani, Bahar, et al.
Publicado: (2023)

1934. Nirsevimab is Associated with Higher and More Sustained RSV Neutralizing Antibody Responses Compared with Standard of Care Palivizumab: Observations from a 2:1 Randomized, Phase 2/3 Trial in Medically Vulnerable Children (MEDLEY)
por: Wilkins, Deidre, et al.
Publicado: (2023)

Efficacy of nirsevimab against respiratory syncytial virus lower respiratory tract infections in preterm and term infants, and pharmacokinetic extrapolation to infants with congenital heart disease and chronic lung disease: a pooled analysis of randomised controlled trials
por: Simões, Eric A F, et al.
Publicado: (2023)

A Single Dose Monoclonal Antibody (mAb) Immunoprophylaxis Strategy to Prevent RSV Disease in All Infants: Results of the First in Infant Study with MEDI8897
por: Domachowske, Joseph B, et al.
Publicado: (2017)

901. MEDI8897 Prevents Serious RSV Disease in Healthy Preterm Infants
por: Pamela Griffin, Mary, et al.
Publicado: (2019)

89. The Impact of Nirsevimab on an RSV Season in All Infants: Data From The HARMONIE Study
por: Faust, Saul N, et al.
Publicado: (2023)

94. Pooled analysis of nirsevimab resistance through 150 days post dose in preterm and term infants
por: Abram, Michael E, et al.
Publicado: (2022)

2641. Nirsevimab binding-site conservation in RSV F protein between 2015 and 2022: The US OUTSMART-RSV surveillance study
por: Morehouse, Christopher A, et al.
Publicado: (2023)

Safety, Tolerability and Pharmacokinetics of MEDI8897, an Extended Half-life Single-dose Respiratory Syncytial Virus Prefusion F-targeting Monoclonal Antibody Administered as a Single Dose to Healthy Preterm Infants
por: Domachowske, Joseph B., et al.
Publicado: (2018)

Potential Impact of Nirsevimab on RSV Transmission and Medically Attended Lower Respiratory Tract Illness Caused by RSV: A Disease Transmission Model
por: Voirin, Nicolas, et al.
Publicado: (2021)

The efficacy and safety of nirsevimab for the prevention of RSV infection among infants: A systematic review and meta-analysis
por: Turalde-Mapili, Maria Wilma R., et al.
Publicado: (2023)

Expected Impact of Universal Immunization With Nirsevimab Against RSV-Related Outcomes and Costs Among All US Infants in Their First RSV Season: A Static Model
por: Kieffer, Alexia, et al.
Publicado: (2022)

Safety, Tolerability, and Pharmacokinetics of MEDI8897, the Respiratory Syncytial Virus Prefusion F-Targeting Monoclonal Antibody with an Extended Half-Life, in Healthy Adults
por: Griffin, M. Pamela, et al.
Publicado: (2017)

Inequalities in Health Impact of Alternative Reimbursement Pathways for Nirsevimab in the United States
por: Gomez, Gabriela B, et al.
Publicado: (2022)

Characterization of Circulating RSV Strains Among Patients In The Outsmart RSV Program During the 2015–16 Winter Viral Season in the United States
por: Pastula, Susan, et al.
Publicado: (2017)

RSV Disease: Current Management and the Future of Treatment and Prevention
por: Krilov, Leonard R., et al.
Publicado: (2021)

An Adjuvanted, Postfusion F Protein–Based Vaccine Did Not Prevent Respiratory Syncytial Virus Illness in Older Adults
por: Falloon, Judith, et al.
Publicado: (2017)

Safety, pharmacokinetics and pharmacodynamics of the selective glucocorticoid receptor modulator AZD7594, following inhalation in healthy Japanese volunteers
por: Prothon, Susanne, et al.
Publicado: (2019)

Characterization of circulating RSV strains among subjects in the OUTSMART-RSV surveillance program during the 2016-17 winter viral season in the United States
por: Ruzin, Alexey, et al.
Publicado: (2018)

Pharmacokinetics of the Oral Selective CXCR2 Antagonist AZD5069: A Summary of Eight Phase I Studies in Healthy Volunteers
por: Cullberg, Marie, et al.
Publicado: (2018)

Nirsevimab brings breakthrough in the prevention of respiratory syncytial virus infection in infants – Importance of design
por: Zhaori, Getu
Publicado: (2023)

Longitudinal FEV(1) and Exacerbation Risk in COPD: Quantifying the Association Using Joint Modelling
por: Zhudenkov, Kirill, et al.
Publicado: (2021)

Dose Selection for an Adjuvanted Respiratory Syncytial Virus F Protein Vaccine for Older Adults Based on Humoral and Cellular Immune Responses
por: Falloon, Judith, et al.
Publicado: (2017)

Coadministration of Anti-Viral Monoclonal Antibodies With Routine Pediatric Vaccines and Implications for Nirsevimab Use: A White Paper
por: Esposito, Susanna, et al.
Publicado: (2021)

Fc-mediated functions of nirsevimab complement direct respiratory syncytial virus neutralization but are not required for optimal prophylactic protection
por: Brady, Tyler, et al.
Publicado: (2023)

Efficacy and safety of AZD7594, an inhaled non-steroidal selective glucocorticoid receptor modulator, in patients with asthma: a phase 2a randomized, double blind, placebo-controlled crossover trial
por: Brown, Mary N., et al.
Publicado: (2019)

Navafenterol (AZD8871) in patients with COPD: a randomized, double-blind, phase I study evaluating safety and pharmacodynamics of single doses of this novel, inhaled, long-acting, dual-pharmacology bronchodilator
por: Singh, Dave, et al.
Publicado: (2020)

Navafenterol (AZD8871) in patients with mild asthma: a randomised placebo-controlled phase I study evaluating the safety, tolerability, pharmacokinetics, and pharmacodynamics of single ascending doses of this novel inhaled long-acting dual-pharmacology bronchodilator
por: Jimenez, Eulalia, et al.
Publicado: (2020)

Navafenterol (AZD8871) in healthy volunteers: safety, tolerability and pharmacokinetics of multiple ascending doses of this novel inhaled, long-acting, dual-pharmacology bronchodilator, in two phase I, randomised, single-blind, placebo-controlled studies
por: Balaguer, Victor, et al.
Publicado: (2020)

Safety and Immunogenicity of a ChAd155-Vectored Respiratory Syncytial Virus (RSV) Vaccine in Healthy RSV-Seropositive Children 12–23 Months of Age
por: Díez-Domingo, Javier, et al.
Publicado: (2022)

RSV glycoprotein and genomic RNA dynamics reveal filament assembly prior to the plasma membrane
por: Vanover, Daryll, et al.
Publicado: (2017)

Is it RSV?
por: Ambrose, Christopher S.
Publicado: (2018)

Global molecular diversity of RSV – the “INFORM RSV” study
por: Langedijk, Annefleur C., et al.
Publicado: (2020)

Use of Nirsevimab for the Prevention of Respiratory Syncytial Virus Disease Among Infants and Young Children: Recommendations of the Advisory Committee on Immunization Practices — United States, 2023
por: Jones, Jefferson M., et al.
Publicado: (2023)

RSV Replication, Transmission, and Disease Are Influenced by the RSV G Protein
por: Bergeron, Harrison C., et al.
Publicado: (2022)

Cost-effectiveness analysis of nirsevimab and maternal RSVpreF vaccine strategies for prevention of Respiratory Syncytial Virus disease among infants in Canada: a simulation study
por: Shoukat, Affan, et al.
Publicado: (2023)

RSV A2-Based Prefusion F Vaccine Candidates Induce RSV A and RSV B Cross Binding and Neutralizing Antibodies and Provide Protection against RSV A and RSV B Challenge in Preclinical Models
por: Cox, Freek, et al.
Publicado: (2023)

An outbreak of RSV infections in a neonatology clinic during the RSV-season
por: Vakrilova, Liliya, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_9rgnkcofgh57g1462hbfudqf62